Switzerland
  • /
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • People
  • US
  • UK
  • Germany
  • France
  • Africa
  • CH
  • @

Categories

  • ABB
  • Alps
  • Basel
  • Bern
  • Chubb
  • Geneva
  • Glencore
  • Lausanne
  • Nestlé
  • Novartis
  • Roche
  • Switzerland
  • UBS
  • Vitol
  • Zürich
  • Zurich Insurance
Switzerland
  • /
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • People
  • US
  • UK
  • Germany
  • France
  • Africa
  • CH
  • @

Browsing Tag

Pharma

118 posts
NNovartis
Novartis confirms more reported tumor cases in Zolgensma patients as SMA groups seek details
Read More

Novartis confirms more reported tumor cases in Zolgensma patients as SMA groups seek details

  • 2026-11-22
Novartis has confirmed a number of new cases of tumors that developed in children treated with its gene…
RRoche
Roche, Asahi Kasei, Verastem—Fierce Pharma Asia
Read More

Roche, Asahi Kasei, Verastem—Fierce Pharma Asia

  • 2026-11-22
Roche extended its China shopping spree with a $1 billion-plus obesity deal. Asahi Kasei’s Hovilpri became the first…
RRoche
Sales of Roche's juggernaut Vabysmo rout the analyst consensus
Read More

Sales of Roche’s juggernaut Vabysmo rout the analyst consensus

  • 2026-11-22
It’s been eight months since Regeneron secured approval for a high-dose version of its powerhouse macular degeneration treatment Eylea…
NNovartis
FDA probes Novartis’ Zolgensma gene therapy over cancer risks
Read More

FDA probes Novartis’ Zolgensma gene therapy over cancer risks

  • 2026-11-22
The FDA has launched a safety investigation into Novartis’ gene therapy Zolgensma following reports of tumors in patients,…
NNovartis
Novartis buffers price erosion with Cosentyx's 11th FDA nod
Read More

Novartis buffers price erosion with Cosentyx’s 11th FDA nod

  • 2026-11-22
Novartis is eking out the life of its aging immunology med, Cosentyx, with another label expansion. The anti-IL-17…
RRoche
Roche pauses future Germany investments
Read More

Roche pauses future Germany investments

  • 2026-11-22
Amid tensions over government healthcare cost-cutting policies, Roche has slammed the brakes on new investments in Germany, joining…
NNovartis
Novartis stares down $16.7B post-2030 patent cliff
Read More

Novartis stares down $16.7B post-2030 patent cliff

  • 2026-11-22
Novartis is gearing up to defend its growth trajectory against a steep wave of patent expirations in the…
RRoche
Roche’s Gazyva wins first FDA nod for membranous nephropathy
Read More

Roche’s Gazyva wins first FDA nod for membranous nephropathy

  • 2026-11-22
As Roche’s Gazyva comes under pressure in blood cancer, the anti-CD20 antibody keeps expanding its reach in autoimmune…
RRoche
Roche’s next major breast cancer drug, Wilserdly, wins FDA nod
Read More

Roche’s next major breast cancer drug, Wilserdly, wins FDA nod

  • 2026-11-22
No breast cancer asset in Roche’s pipeline carries a higher valuation than giredestrant. In fact, the Swiss drugmaker’s…
RRoche
Vabysmo shows signs of recovery as Roche gears up for busy 2027
Read More

Vabysmo shows signs of recovery as Roche gears up for busy 2027

  • 2026-11-22
After disappointing Wall Street for most of 2026, Roche’s eye disease drug Vabysmo met analysts’ expectations for the…
RRoche
Roche-Hanmi, Akeso, a congressman's concerns—Fierce Pharma Asia
Read More

Roche-Hanmi, Akeso, a congressman’s concerns—Fierce Pharma Asia

  • 2026-11-22
With a potential $2.5 billion deal with Hanmi, Roche is taking a less-trodden path in obesity. Akeso’s CEO…
NNovartis
Novartis Remains on a Growth Trajectory Despite Expiring Patents
Read More

Novartis Remains on a Growth Trajectory Despite Expiring Patents

  • 2026-11-19
Pharmaceuticals Novartis Remains on a Growth Trajectory Despite Expiring Patents (File photo) Keystone At its Investor Day, Novartis…
Switzerland
www.europesays.com